Sunshine BiopharmaSBFM -2.34%34 3-Year ROIIC % is 33.10 as of Dec. 2025, which is 42% below its 10-year median of 56.85. GuruFocus rates SBFM with a GF Score™ of 34/100 and a GF Value™ of $7.23 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 944 Drug Manufacturers companies, Sunshine Biopharma ranks better than 77.65% on this metric.
3-Year Return on Invested Incremental Capital (3-Year ROIIC %) measures the change in earnings as a percentage of change in investment over 3-year.
Sunshine Biopharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 was 33.10%. High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
The industry rank for Sunshine Biopharma's 3-Year ROIIC % or its related term are showing as below:
SBFM's 3-Year ROIIC % is ranked better than 77.65% of 944
companies
in the Drug Manufacturers industry
Industry Median: 3.635
vs SBFM: 33.10
Return on Incremental Invested Capital (ROIIC) is an extension of Return on Investment Capital (ROIC). ROIC % tells investors how efficiently that profitability is earned per dollar of company capital. ROIIC narrows the focus even further and shows how profitable each additional unit of capital investment could be. ROIIC % is a more powerful metric than ROIC because it measures how much money the company can generate going forward on future capital investments.
High ROIIC is generally an indication that your business is capital efficient or has a higher operating leverage.
Be Aware
It's important to keep in mind that when tracking ROIIC, the metric is better suited to forecasting the trend of future returns rather than measuring current return on investment.
Sunshine Biopharma 3-Year ROIIC % Related Terms
Sunshine Biopharma 3-Year ROIIC % Historical Data
* Premium members only.
The historical data trend for Sunshine Biopharma's 3-Year ROIIC % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBFM vs PRFX, CTTH, CVSI: 3-Year ROIIC % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Sunshine Biopharma's 3-Year ROIIC %, along with its competitors' market caps and 3-Year ROIIC % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Biopharma 3-Year ROIIC % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Sunshine Biopharma's 3-Year ROIIC % distribution charts can be found below:
* The bar in red indicates where Sunshine Biopharma's 3-Year ROIIC % falls into.
Sunshine Biopharma's 3-Year ROIIC % for the quarter that ended in Dec. 2025 is calculated as:
3-Year ROIIC %
=
3-Year Incremental Net Operating Profit After Taxes (NOPAT)**
/
3-Year Incremental Invested Capital**
=
( -4.479 (Dec. 2025) - -8.674 (Dec. 2022) )
/
( 14.728 (Dec. 2025) - 2.055 (Dec. 2022) )
=
4.195
/
12.673
=
33.10%***
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** Annual data of NOPAT and Invested Capital was used to calculate 3-Year ROIIC %.
*** Please be aware that the ROIIC (Return on Invested Capital) calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.
Sunshine Biopharma (SBFM) has a 3-Year ROIIC % of 33.10 as of Dec. 2025. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sunshine Biopharma and its competitors. This is 42% below median its historical median of 56.85. According to the industry distribution chart, Sunshine Biopharma ranks #211 out of 944 companies in the Drug Manufacturers industry, placing it in the top 22.4%.
Is Sunshine Biopharma's 3-Year ROIIC % too high?
Sunshine Biopharma's current 3-Year ROIIC % of 33.10 is 42% below median its 10-year median of 56.85. The Drug Manufacturers industry median 3-Year ROIIC % is 3.64. Sunshine Biopharma's value of 33.10 is 810.6% above this industry median. Based on the distribution chart, Sunshine Biopharma ranks #211 out of 944 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sunshine Biopharma has a GF Score™ of 34/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sunshine Biopharma's 3-Year ROIIC % compare to PRFX and CTTH?
According to the Drug Manufacturers industry distribution chart, Sunshine Biopharma ranks #211 out of 944 companies for 3-Year ROIIC %. This places Sunshine Biopharma in the top 22% of its industry — outperforming the majority of peers. The industry median 3-Year ROIIC % is 3.64. Sunshine Biopharma's value of 33.10 is 810.6% above this benchmark. While the company's 10-year median is 56.85 vs. the industry median of 3.64, Sunshine Biopharma has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year ROIIC % for a Drug Manufacturers company?
The median 3-Year ROIIC % among Drug Manufacturers companies is 3.64, based on 944 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year ROIIC % significantly above this median, while those in the bottom quartile fall well below. However, 3-Year ROIIC % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Biopharma's current 3-Year ROIIC % of 33.10 is 810.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year ROIIC % mean?
A high 3-Year ROIIC % can signal that a stock is expensive relative to its fundamentals. 3-Year ROIIC % measures the change in earnings as a percentage of change in investment over 3-year. View historical data on Sunshine Biopharma and its competitors. For the Drug Manufacturers industry, the median 3-Year ROIIC % is 3.64 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Biopharma's current 3-Year ROIIC % is 33.10, which is 42% below median its own 10-year median of 56.85. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Biopharma (SBFM) is currently considered Possible Value Trap. The stock's GF Value™ is $7.23, compared to a current price of $2.12 — trading 70.7% below its estimated fair value. The current 3-Year ROIIC % is 33.10, which is 42% below median its 10-year median of 56.85 and 810.6% above the Drug Manufacturers industry median of 3.64. Sunshine Biopharma's overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year ROIIC % calculated?
3-Year ROIIC % is calculated from a company's financial statements. For Sunshine Biopharma (SBFM), the current 3-Year ROIIC % is 33.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Biopharma (SBFM) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Biopharma stock appears to be undervalued.
The current stock price of $2.12 is trading 70.7% below its estimated GF Value™ of $7.23.
GuruFocus considers Sunshine Biopharma to be Possible Value Trap.
Key valuation signals for SBFM:
3-Year ROIIC %: 33.10 (42% below median its 10-year median of 56.85)
GF Value™: $7.23 vs. price of $2.12 (70.7% below fair value)
Industry Position: 810.6% above the Drug Manufacturers median (#211 of 944)
No single metric tells the full story. See the SBFM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Biopharma Inc is a pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. Through its subsidiaries, the company has various generic prescription drugs on the market in Canada and is also involved in developing and selling OTC supplements. In addition, the company is conducting a proprietary drug development program, which is comprised of K1.1 mRNA targeted for liver cancer and SBFM-PL4, PLpro protease inhibitor for SARS Coronavirus infections.
34GF Score
Get the complete analysis for SBFM
3-Year ROIIC % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBFM has been successfully added to your 
